Bio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical & Diagnostic Laboratories
- Sub-Industry: Health Care Services
- Symbol: NASDAQ:BRLI
- CUSIP: 09057G60
- Web: www.bioreference.com
- 50 Day Moving Avg: $41.81
- 200 Day Moving Avg: $36.97
- 52 Week Range: $26.32 - $47.49
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 14.98
- P/E Growth: 0.00
- Net Margins: 4.67%
- Return on Equity: 12.67%
- Return on Assets: 8.38%
- Average Volume: 653,202 shs.
Frequently Asked Questions for Bio-Reference Laboratories (NASDAQ:BRLI)
What is Bio-Reference Laboratories' stock symbol?
Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."
How were Bio-Reference Laboratories' earnings last quarter?
Bio-Reference Laboratories Inc (NASDAQ:BRLI) announced its quarterly earnings data on Thursday, December, 18th. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.63 by $0.03. The business earned $227.60 million during the quarter, compared to the consensus estimate of $228.81 million. Bio-Reference Laboratories had a net margin of 4.67% and a return on equity of 12.67%. The company's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.40 EPS. View Bio-Reference Laboratories' Earnings History.
Who are some of Bio-Reference Laboratories' key competitors?
Some companies that are related to Bio-Reference Laboratories include Partnership Assurance Group PLC (PA), Johnson & Johnson (JNJ), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Koninklijke Philips NV (PHG), Shire PLC (SHP), Edwards Lifesciences Corp (EW), Hospira (HSP), IDEXX Laboratories (IDXX), Smith & Nephew plc (SN), Teleflex Incorporated (TFX), Omnicare (OCR), Alkermes Plc (ALKS), VCA (WOOF), Henry Schein (HSIC), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC) and ConvaTec Group PLC (CTEC).
How do I buy Bio-Reference Laboratories stock?
Shares of Bio-Reference Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio-Reference Laboratories' stock price today?
MarketBeat Community Rating for Bio-Reference Laboratories (NASDAQ BRLI)MarketBeat's community ratings are surveys of what our community members think about Bio-Reference Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Bio-Reference Laboratories stock can currently be purchased for approximately $34.61.
Consensus Ratings for Bio-Reference Laboratories (NASDAQ:BRLI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Bio-Reference Laboratories (NASDAQ:BRLI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Bio-Reference Laboratories (NASDAQ:BRLI)Earnings History by Quarter for Bio-Reference Laboratories (NASDAQ BRLI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/8/2015||Q215||$0.46||$0.38||$227.33 million||$224.00 million||View||Listen|
|3/5/2015||Q115||$0.36||$0.24||$216.40 million||$209.00 million||View||Listen|
|12/18/2014||Q414||$0.63||$0.66||$228.81 million||$227.60 million||View||Listen|
|8/27/2014||Q314||$0.53||$0.55||$210.44 million||$222.10 million||View||Listen|
|6/5/2014||Q214||$0.32||$0.37||$0.20 million||$201.30 million||View||Listen|
|3/4/2014||Q114||$0.14||$0.11||$175.52 million||$181.30 million||View||Listen|
|12/19/2013||Q4||$0.40||$0.40||$188.96 million||$192.20 million||View||Listen|
|8/29/2013||Q3 2013||$0.51||$0.53||$183.50 million||$185.40 million||View||Listen|
|6/6/2013||Q2 2013||$0.41||$0.41||$176.04 million||$176.50 million||View||Listen|
|2/28/2013||Q1 2013||$0.28||$0.31||$165.44 million||$161.30 million||View||Listen|
|8/30/2012||Q312||$0.43||$0.45||$0.17 million||$0.17 million||View||N/A|
|12/16/2010||$0.30||$0.31||$124.19 million||$126.60 million||View||N/A|
Earnings Estimates for Bio-Reference Laboratories (NASDAQ:BRLI)
Current Year EPS Consensus Estimate: $1.98 EPS
Next Year EPS Consensus Estimate: $2.31 EPS
Dividend History for Bio-Reference Laboratories (NASDAQ:BRLI)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Bio-Reference Laboratories (NASDAQ:BRLI)
Latest Headlines for Bio-Reference Laboratories (NASDAQ:BRLI)
Bio-Reference Laboratories (BRLI) Chart for Monday, September, 25, 2017